Financial Performance - The company's revenue for the year ended December 31, 2025, was SGD 18,586,000, representing a 77.8% increase from SGD 10,459,000 in 2024[4] - Gross profit for the same period was SGD 3,318,000, compared to SGD 228,000 in 2024, indicating a significant improvement[4] - The company reported a net loss of SGD 612,000 for 2025, a reduction from a net loss of SGD 2,631,000 in 2024, reflecting a 76.8% decrease in losses[5] - Total segment revenue for the year ending December 31, 2025, is SGD 18,586,000, with the medical components segment contributing SGD 10,580,000[23] - The medical components segment reported a profit of SGD 2,366,000, while the total segment profit was SGD 3,312,000[23] - The company reported a loss before tax of 600 thousand Singapore dollars for 2025, compared to a loss of 2,785 thousand Singapore dollars in 2024, indicating an improvement in financial performance[34] - The overall gross profit increased from approximately SGD 0.2 million in FY2024 to approximately SGD 3.3 million in FY2025, with the gross profit margin rising from a loss margin of about 2.2% to a profit margin of approximately 17.9%[51] - The net loss for FY2025 was approximately SGD 0.6 million, significantly reduced from a loss of SGD 2.6 million in FY2024[47] Assets and Liabilities - Total assets decreased to SGD 6,407,000 in 2025 from SGD 6,491,000 in 2024, while total liabilities increased to SGD 6,048,000 from SGD 3,550,000[6] - The company's equity attributable to owners decreased to SGD 1,524,000 in 2025 from SGD 2,141,000 in 2024, reflecting a decline in shareholder value[7] - Current liabilities due within one year as of December 31, 2025, amount to approximately SGD 6,048,000, while cash and bank balances are around SGD 1,190,000[11] - Total liabilities rose to 7,414 thousand Singapore dollars in 2025 from 6,627 thousand Singapore dollars in 2024, marking an increase of 11.9%[26] Cash Flow and Liquidity - The company's cash and cash equivalents decreased to SGD 1,190,000 in 2025 from SGD 1,779,000 in 2024, indicating a liquidity challenge[6] - The current ratio decreased to approximately 1.1 times as of December 31, 2025, from 1.8 times in FY2024, mainly due to a reduction in cash and cash equivalents and an increase in borrowings[61] - Cash and cash equivalents were approximately SGD 1.2 million as of December 31, 2025, down from SGD 1.8 million in FY2024[61] Borrowings and Financial Costs - The company incurred finance costs of SGD 278,000 in 2025, up from SGD 167,000 in 2024, indicating increased borrowing costs[4] - The company has a significant amount of borrowings, with SGD 1,084,000 in loans in 2025 compared to SGD 531,000 in 2024, indicating increased leverage[6] - Financial costs rose from approximately SGD 0.2 million in FY2024 to about SGD 0.3 million in FY2025, attributed to accrued interest from a shareholder loan[60] Revenue Sources and Business Operations - The company is primarily engaged in the manufacturing and sale of disposable medical devices and is exploring data solutions and services in mainland China[8] - The company has diversified its revenue sources by expanding into data solutions and hotel-related businesses, contributing to the overall revenue growth[47] - Major customer A contributed 10,589 thousand Singapore dollars to total revenue in 2025, up from 7,859 thousand Singapore dollars in 2024, while customer B's contribution was not applicable in 2025[27] - The geographical distribution of external customer revenue showed that mainland China contributed 6,552 thousand Singapore dollars in 2025, a substantial increase from 841 thousand Singapore dollars in 2024[28] Expenses and Other Income - Research and development expenses decreased to 403 thousand Singapore dollars in 2025 from 559 thousand Singapore dollars in 2024, a reduction of 27.9%[31] - Other income decreased by approximately SGD 0.5 million or 62.5% from about SGD 0.8 million in FY2024 to about SGD 0.3 million in FY2025, primarily due to a reduction in government grants[52] - The company recorded a net other loss of approximately SGD 0.2 million in FY2025, compared to a net other income of approximately SGD 0.2 million in FY2024, mainly due to foreign exchange losses[53] - Administrative expenses increased by approximately SGD 0.5 million or 18.5% from about SGD 2.7 million in FY2024 to approximately SGD 3.2 million in FY2025, driven by increased professional service costs due to business expansion[58][59] Shareholder Information and Corporate Governance - The board did not recommend the distribution of a final dividend for the year ending December 31, 2025[76] - As of December 31, 2025, Mr. Pan Ruihe holds 33,832,000 shares, representing 4.13% of the company's total shares[77] - Mr. Xie Jianlong owns 61,612,000 shares, accounting for 7.53% of the company's total shares, while Ms. Wu Haiyan holds 52,694,000 shares, representing 6.44%[79] - The company has adhered to the corporate governance code as per GEM listing rules, except for the separation of roles between the Chairman and CEO, which is currently held by Mr. Pan[88] - All directors confirmed compliance with the trading standards for securities transactions during the fiscal year 2025, with no known non-compliance events[89] Audit and Compliance - The auditor, Zhongzheng Tianheng CPA, will present a resolution for reappointment at the upcoming annual general meeting[91] - The auditor has verified that the financial figures in the performance announcement are consistent with the audited financial statements for the year ending December 31, 2025[92] - The audit committee, consisting of three independent non-executive directors, has reviewed the audited financial information and confirmed compliance with applicable accounting standards and GEM listing rules[93]

Financial Performance - The company's revenue for the year ended December 31, 2025, was SGD 18,586,000, representing a 77.8% increase from SGD 10,459,000 in 2024[4] - Gross profit for the same period was SGD 3,318,000, compared to SGD 228,000 in 2024, indicating a significant improvement[4] - The company reported a net loss of SGD 612,000 for 2025, a reduction from a net loss of SGD 2,631,000 in 2024, showing progress in financial performance[5] - The group recorded a loss of approximately SGD 612,000 and SGD 2,631,000 for the years ending December 31, 2025, and December 31, 2024, respectively[11] - The company reported a loss before tax of SGD 600,000 for 2025, compared to a loss of SGD 2,785,000 in 2024, indicating a significant improvement[34] - The net loss for FY2025 was significantly reduced to about SGD 0.6 million from SGD 2.6 million in FY2024, attributed to increased revenue contributions from diversified business sectors[47] Assets and Liabilities - Total assets decreased to SGD 6,407,000 in 2025 from SGD 6,491,000 in 2024, reflecting a slight decline in asset management[6] - Current liabilities increased to SGD 6,048,000 in 2025 from SGD 3,550,000 in 2024, indicating a rise in short-term financial obligations[6] - Non-current liabilities decreased significantly to SGD 1,366,000 in 2025 from SGD 3,077,000 in 2024, indicating improved long-term financial stability[7] - The company's equity attributable to owners decreased to SGD 1,524,000 in 2025 from SGD 2,141,000 in 2024, reflecting a decline in shareholder value[7] - The total liabilities rose to SGD 7,414,000 in 2025 from SGD 6,627,000 in 2024, primarily due to increased component liabilities[26] Cash Flow and Liquidity - The company's cash and cash equivalents decreased to SGD 1,190,000 in 2025 from SGD 1,779,000 in 2024, highlighting liquidity challenges[6] - Current liabilities due within one year as of December 31, 2025, amount to approximately SGD 6,048,000, while cash and bank balances are around SGD 1,190,000[11] - Current ratio decreased to approximately 1.1 times as of December 31, 2025, from 1.8 times in FY2024, due to a reduction in cash and cash equivalents and an increase in borrowings[61] Revenue Segments - Total segment revenue for the year ending December 31, 2025, is SGD 18,586,000, with the medical components segment contributing SGD 10,580,000[23] - Major customer A contributed SGD 10,589,000 to total revenue in 2025, up from SGD 7,859,000 in 2024, while customer B's contribution dropped below 10% of total revenue[27] - Revenue from the mainland China market surged to SGD 6,552,000 in 2025, compared to SGD 841,000 in 2024, highlighting significant market expansion[28] Operational Strategy - The company continues to focus on manufacturing and selling disposable medical devices and providing data solutions, indicating ongoing commitment to core business areas[8] - The group plans to raise additional funds through equity financing and long-term debt financing to cover operational costs and repay existing debts[13] - The group aims to negotiate with lenders to extend repayment terms for loans and payables until sufficient operational funds are available[13] - The company introduced new revenue streams from data solutions and hotel-related businesses, diversifying its income sources[47] Expenses and Costs - Research and development expenses decreased to SGD 403,000 in 2025 from SGD 559,000 in 2024, indicating a potential shift in strategic focus[31] - Administrative expenses rose by approximately SGD 0.5 million or 18.5% from about SGD 2.7 million in FY2024 to about SGD 3.2 million in FY2025, mainly due to increased professional service costs related to business expansion[58][59] - Financial costs increased from approximately SGD 0.2 million in FY2024 to approximately SGD 0.3 million in FY2025, attributed to accrued interest from a shareholder loan[60] Shareholder Information - The average number of ordinary shares issued increased to 81,846,000 in 2025 from 74,035,000 in 2024, affecting the calculation of basic loss per share[36] - The company raised approximately SGD 9.7 million from the issuance of new ordinary shares at a net price of about SGD 0.071 per share[72][73] - No final dividend was recommended for the year ending December 31, 2025[76] Governance and Compliance - The company has adhered to the corporate governance code as per GEM listing rules, except for the separation of roles between the Chairman and CEO, which is currently held by Mr. Pan[88] - All directors confirmed compliance with the trading standards for securities transactions during the fiscal year 2025, with no known non-compliance events[89] - The audit committee, consisting of three independent non-executive directors, has reviewed the audited financial information and confirmed compliance with applicable accounting standards and GEM listing rules[93] Market Conditions - The company remains cautious about geopolitical tensions, inflationary pressures, and global economic fluctuations impacting its operations[48] - There is significant uncertainty regarding the management's ability to achieve the expected results from the implemented measures, which may affect the group's ability to continue as a going concern[12]

承董事會命 加和國際控股有限公司 主席 潘瑞河 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致之任何 損失承擔任何責任。 MaxWin International Holdings Limited 加和國際控股有限公司 (於開曼群島註冊成立的有限公司) (股份代號: 8513) 董事會會議通告 加和國際控股有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此通告，董事會將 於二零二六年三月三十日（星期一）舉行董事會會議，以商討下列事項： 新加坡，二零二六年三月十七日 於本公告日期，執行董事為潘瑞河先生、李仁剛先生、徐斌先生及楊淇鈞先生；以及獨立非執行董事為陳 藝華女士、張嘉裕教授及傅思安先生。 本公告的資料乃遵照香港聯合交易所有限公司的 GEM 證券上市規則而刊載，旨在提供有關本公司的資料； 董事願就本公告的資料共同及個別地承擔全部責任。各董事在作出一切合理查詢後，確認就其所知及所信， 本公告所載資料在各重要方面均屬準確完備，沒有誤導或欺詐成分，且並無遺漏任何事項，足以令 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 重新提交 致：香港交易及結算所有限公司 公司名稱: 加和國際控股有限公司 呈交日期: 2026年3月2日 II. 已發行股份及/或庫存股份變動及足夠公眾持股量的確認 1. 股份分類 普通股 股份類別 不適用 於香港聯交所上市 (註1) 是 證券代號 (如上市) 08513 說明 已發行股份（不包括庫存股份）數目 庫存股份數目 已發行股份總數 上月底結存 81,845,537 0 81,845,537 增加 / 減少 (-) 0 本月底結存 81,845,537 0 81,845,537 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08513 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 加和國際控股有限公司 呈交日期: 2026年3月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08513 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | HKD | | 0.01 | HKD | | 10,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 1,000,000,000 | HKD | | 0.01 | HKD | | 10,000,000 | 本月底法定/註冊股本 ...

Group 1 - A total of 78 stocks reached a 52-week high as of February 3, with notable performers including Asia Pacific Financial Investments (08193) at 57.14%, Chao Wei Holdings (08059) at 36.00%, and Asia Backup (08290) at 33.33% [1] - The closing prices for the top three stocks that reached new highs were 0.550, 0.052, and 0.024 respectively, with their highest prices being 0.550, 0.068, and 0.036 [1] - Other significant stocks that reached new highs include Huameilele (08429) with a high rate of 20.37% and Haode Holdings (08149) at 17.65% [1] Group 2 - The report also lists stocks that reached 52-week lows, with the worst performer being Gaodi Holdings (01676) at -10.00%, followed by Huajian Medical (01931) at -9.29% and Electronic Trading Group (08036) at -9.09% [3] - The closing prices for the stocks that reached new lows include 0.340, 1.280, and 0.021 respectively, with their lowest prices being 0.315, 1.270, and 0.020 [3] - Other notable stocks that reached new lows include Controllon (01912) at -8.93% and Cool Link (08491) at -8.11% [3]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 加和國際控股有限公司 呈交日期: 2026年2月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08513 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 HKD | | | 100,000,000 | | 增加 / 減少 (-) | | | -9,000,000,000 | | | HKD | | | | | 本月底結存 | | | 1,000,000,000 | HKD | | 0.1 HKD | | | 100,000 ...

Group 1 - The company, 加和国际控股 (08513), announced a share consolidation of 737 million shares due to a "10-for-1" basis, effective on January 8, 2026 [1]

Core Viewpoint - The company, 加和国际控股 (08513), announced a share consolidation of 737 million shares due to a "10-for-1" basis effective on January 8, 2026 [1] Group 1 - The share consolidation will reduce the total number of shares outstanding by 737 million [1] - The consolidation is part of a strategic move to enhance the company's share value and market perception [1] - The effective date for the share consolidation is set for January 8, 2026 [1]

香港聯合交易所有限公司 (香港交易及結算所有限公司全資附屬公司) 監管表格 上市申請表格 G表格 GEM 公司資料報表 香港交易及結算所有限公司及香港聯合交易所有限公司對本資料報表的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示概不對因本資料報表全部或任何部分內容而產生 或因倚賴該等內容而引致的任何損失承擔任何責任。 公司名稱： 加和國際控股有限公司 證券代號（普通股）： 8513 本資料報表列載若干有關上述在香港聯合交易所有限公司（「交易所」） GEM上市的公司 （「該公司」）的資料。該等資料乃遵照香港聯合交易所有限公司《GEM證券上市規則》 （「《GEM上市規則》」）的規定而提供，旨在向公眾提供有關該公司的資料。該等資料將 會在互聯網的聯交所網頁展示。本資料報表不應視作有關該公司及╱或其證券的完整資料概要。 本報表的資料乃於 2026 年 1 月 8日 更新。 A. 一般資料 註冊成立地點: 開曼群島 在 GEM 首次上市日期: 2018 年 1 月 19 日 保薦人名稱: 不適用 FF003G Page 1 of 5 2023 年 12 月 G表格 FF003G 董事姓名（請列明董事的身 ...